Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2024 Mar 5;4(5):20230138. doi: 10.1002/EXP.20230138

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2024 The Author(s). Exploration published by Henan University and John Wiley & Sons Australia, Ltd.

This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Challenges and future directions for DM‐TB control. First, further research is needed to understand the mechanisms linking DM and LTBI reactivation, potentially providing immunological targets for preventing TB in DM patients. Early screening and intervention for LTBI in DM patients is proposed, utilizing TST and IGRA for screening and implementing TPT treatment as early intervention. Additionally, since DM reduces the sensitivity of immunological tests for TB, exploring more accurate biomarkers through methods like genomics is suggested for diagnosing DM‐LTBI. Machine learning can also aid in screening and prognostic evaluation for DM‐TB patients. Finally, candidate biomarkers require clinical trials to validate their clinical utility. DM, diabetes mellitus; IGRA, interferon‐gamma release assay; TB, tuberculosis; TPT, TB preventive therapy; TST, tuberculin skin test; LTBI, latent tuberculosis infection.